The CD133+ cancer stem cell (CSC) fraction, ranging from 19 to 29% in highly aggressive glioblastomas and from 6 to 21% in MBs, correlated closely with an in vitro primary sphere formation assay3. The gene discussed is PROM1; the disease is cancer.